OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Myeloma and marrow adiposity: Unanswered questions and future directions	105
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	103
Editorial Board	73
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	70
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	55
Editorial Board	53
Genetics of pubertal timing	52
Editorial Board	52
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	50
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	44
Menopausal hormone therapy for the management of osteoporosis	42
Coronavirus disease 2019 and vitamin D	42
Regulation of bone mass: A splendid Orchestra	42
Prenatal exposure to phthalate esters and its impact on child development	39
Editorial Board	38
The role of androgens in transgender medicine	37
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	37
Sexual health and contraception in the menopause journey	36
Immune checkpoint inhibitor-related thyroid dysfunction	36
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	36
Editorial Board	35
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	35
Cardiometabolic outcomes of early onset hypogonadism in males	33
Haematological actions of androgens	32
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	29

Remnant lipoprotein particles and cardiovascular disease risk	29
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	28
Non-oestrogen-based and complementary therapies for menopause	27
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
The effect of osteoporosis treatment on bone mass	26
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	26
Metabolic complications and their mechanisms in patients with craniopharyngioma	25
Type 1 diabetes related to immune checkpoint inhibitors	25
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Medullary thyroid cancer - An update	24
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	23
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	23
Editorial Board	23
Endocrine-disrupting chemicals and behaviour: A high risk to take?	23
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	23
Pathophysiology of thyroid-associated orbitopathy	22
Approach to patients with elevated low-density lipoprotein cholesterol levels	22
Hormone therapy for menopause and premature ovarian insufficiency	22
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Editorial Board	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	21
Safety of androgen therapy in men with prostate cancer	21
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	21
Immune checkpoint inhibitor-related hypophysitis	21
The role of hormone therapy in urogenital health after menopause	20
History of androgens and androgen action	20
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	20
Localization in primary hyperparathyroidism	19
Editorial Board	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Genotype-phenotype correlations in Graves’ disease	18
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	18
Editorial Board	18
Endocrine disrupting chemicals and bone	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
Genetics of anti-Müllerian hormone and its signaling pathway	17
Anaplastic thyroid cancer: An update	17
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Preface	17
Exercise and physical activity in individuals at risk of fracture	16
Care quality improvement in differences of sex development	16
COVID-induced thyroid autoimmunity	16
Editorial Board	15
Preface	15
Chemokines in thyroid autoimmunity	15
Hormone replacement in disorders of sex development, and long-term effects	15
The epidemiology of disorders of sex development	15
Covid-19 and endocrinology	14
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	14

The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	14
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	14
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	14
Paraneoplastic autoimmune hypophysitis: An emerging concept	14
Editorial Board	13
Surgical treatment of thyroid cancer: Established and novel approaches	13
How best to monitor the specific side effects of medical treatments of Cushing’s disease	13
Endocrine abnormality in paraneoplastic syndrome	13
Quality of life in thyroid cancer	12
Menopausal hormone therapy in women with medical conditions	12
SARS-CoV-2 infection and its effects on the endocrine system	12
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	12
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	12
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	11
Adolescent primary hyperparathyroidism	11
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	11
Regulation of bone mass in endocrine diseases including diabetes	10
Real-world value of cabergoline in the treatment of acromegaly	10
Androgen-based therapies in women	10
Management of patients with statin intolerance	9
Publisher's Note	9
Long-term thionamide antithyroid treatment of Graves' disease	9
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	9
Current medical treatment and perspective in gonadotroph tumors	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Genetics of 46,XY gonadal dysgenesis	9
COVID-19 vaccination and thyroiditis	8
Editorial Board	8
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	8
Androgens part 2: Emerging areas	8
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Editorial Board	8
Neural regulation of bone marrow adipose tissue	8
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	8
Burosumab: Current status and future prospects	8
Pituitary and SARS CoV-2: An unremitting conundrum	8
Inherited fibroblast growth factor 23 excess	8
Phthalates, ovarian function and fertility in adulthood	7
Novel androgen therapies including selective androgen receptor modulators	7
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	7
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	7
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	7
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Vitamin D deficiency or resistance and hypophosphatemia	6
Traumatic brain injury and hypopituitarism	5
Tumor-induced osteomalacia: An overview	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Androgen therapy for women after menopause	5
Morbidity and mortality in men: Role of androgens	5
New advances in menopause symptom management	5
Pituitary dysfunction due to sports injuries	5
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	5
Innovative therapeutics in acromegaly	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Management of non-hepatic distant metastases in neuroendocrine neoplasms	4
Androgens, sports, and detection strategies for anabolic drug use	4
Thyroid hormone system disrupting chemicals	4
Editorial Board	4
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
In utero exposure to phthalates and reproductive toxicity in rodents	4
Editorial Board	4
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	4
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	4
Primary hyperparathyroidism	4
Clinical imaging of marrow adiposity	4